Scynexis Inc., of Durham, N.C., said in an S-1/A filing with the SEC that it will seek to raise $62 million in its initial public offering of 6.2 million shares priced at $10 apiece. The company originally filed in February, seeking to raise up to $55 million, setting terms in March to offer 4.2 million shares priced in a range of $12 to $14. In new filings on April 2, the company up-sized the offering, indicating it would seek to raise up to $67.5 million by offering 7.3 million shares at $7 to $8. In the latest filing, Scynexis said it granted underwriters a 30-day option to purchase up to 930,000 additional shares, potentially generating another $9.3 million. Filing as an emerging growth company, Scynexis plans to list on the Nasdaq Global Market as SCYX. RBC Capital Markets and Canaccord Genuity are joint bookrunners on the deal. (See BioWorld Today, March 4, 2014.)